BIOMAT Database Logo BIOMAT Database Logo

CD44/CD70 blockade and anti-CD154/LFA-1 treatment synergistically suppress accelerated rejection and prolong cardiac allograft survival in mice. 2011

W Shao, and G Yan, and Y Lin, and J Chen, and H Dai, and F Wang, and Y Xi, and H Thorlacius, and Z Qi
Department of Pathology, The 174th Hospital of People's Liberation Army, Xiamen University, Fujian Province, China.

Current treatments that are efficient in controlling effector T cell responses to allografts have limited efficacy on the accelerated rejection mediated by memory T cells. Effective targeting of alloreactive memory T cells may therefore be explored to improve therapeutic approaches towards solving this problem. In this study, we investigated the synergistic effect of CD44/CD70 blockade and anti-CD154/LFA-1 treatment on the accelerated rejection mediated by memory T cells. While CD44/CD70 blockade had limited effects on the alloresponses of effector T cells in vivo, it diminished the expansion of both CD4(+) and CD8(+) memory T cells in recipients adoptively transferred with donor-sensitized T cells. In combination with anti-CD154/LFA-1 treatment, CD44/CD70 blockade significantly prolonged cardiac allograft survival in adoptive transfer recipients. We demonstrated that treatment with the combination of all four antibodies (anti-CD154/LFA-1/CD44/CD70) inhibited accelerated rejection by markedly suppressing the alloresponses of effector and memory T cells and reducing the number of graft-infiltration lymphocytes in adoptive transfer recipients. Meanwhile, CD44/CD70 blockade and anti-CD154/LFA-1 treatment synergically enhanced regulatory T cells (Tregs) by increasing the proportion of splenic Tregs and the expression of IL-10 in these recipients. Our findings contribute to the potential design of therapies for accelerated allograft rejection.

UI MeSH Term Description Entries
D007114 Immunization Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow). Immunologic Stimulation,Immunostimulation,Sensitization, Immunologic,Variolation,Immunologic Sensitization,Immunological Stimulation,Sensitization, Immunological,Stimulation, Immunologic,Immunizations,Immunological Sensitization,Immunological Sensitizations,Immunological Stimulations,Sensitizations, Immunological,Stimulation, Immunological,Stimulations, Immunological,Variolations
D007156 Immunologic Memory The altered state of immunologic responsiveness resulting from initial contact with antigen, which enables the individual to produce antibodies more rapidly and in greater quantity in response to secondary antigenic stimulus. Immune Memory,Immunological Memory,Memory, Immunologic,Immune Memories,Immunologic Memories,Immunological Memories,Memory, Immune,Memory, Immunological
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006085 Graft Survival The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. Graft Survivals,Survival, Graft,Survivals, Graft
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal

Related Publications

W Shao, and G Yan, and Y Lin, and J Chen, and H Dai, and F Wang, and Y Xi, and H Thorlacius, and Z Qi
Potent ability of anti-LFA-1 monoclonal antibody to prolong allograft survival.
May 1984, Transplantation,
W Shao, and G Yan, and Y Lin, and J Chen, and H Dai, and F Wang, and Y Xi, and H Thorlacius, and Z Qi
LFA-1 and ICAM-1 antibody-idarubicin conjugates separately prolong murine cardiac allograft survival.
October 2001, Transplant immunology,
W Shao, and G Yan, and Y Lin, and J Chen, and H Dai, and F Wang, and Y Xi, and H Thorlacius, and Z Qi
Monoclonal antibodies against ICAM-1 and LFA-1 prolong nerve allograft survival.
January 1995, Muscle & nerve,
W Shao, and G Yan, and Y Lin, and J Chen, and H Dai, and F Wang, and Y Xi, and H Thorlacius, and Z Qi
CTLA4Ig combined with anti-LFA-1 prolongs cardiac allograft survival indefinitely.
June 2002, Transplant immunology,
W Shao, and G Yan, and Y Lin, and J Chen, and H Dai, and F Wang, and Y Xi, and H Thorlacius, and Z Qi
Rapamycin and cyclosporine synergistically prolong heart and kidney allograft survival.
December 1991, Transplantation proceedings,
W Shao, and G Yan, and Y Lin, and J Chen, and H Dai, and F Wang, and Y Xi, and H Thorlacius, and Z Qi
Prevention of fetal bowel allograft rejection by combined treatment with anti-ICAM-1 and anti-LFA-1 antibodies.
July 1995, Journal of pediatric surgery,
W Shao, and G Yan, and Y Lin, and J Chen, and H Dai, and F Wang, and Y Xi, and H Thorlacius, and Z Qi
Role of ICAM-1 and LFA-1 in cardiac allograft rejection of the rat.
February 1993, Transplantation proceedings,
W Shao, and G Yan, and Y Lin, and J Chen, and H Dai, and F Wang, and Y Xi, and H Thorlacius, and Z Qi
The effect of simultaneous CD154 and LFA-1 blockade on the survival of allogeneic islet grafts in nonobese diabetic mice.
December 2003, Transplantation,
W Shao, and G Yan, and Y Lin, and J Chen, and H Dai, and F Wang, and Y Xi, and H Thorlacius, and Z Qi
Prolongation of primate cardiac allograft survival by treatment with ANTI-CD40 ligand (CD154) antibody.
December 1999, Transplantation,
W Shao, and G Yan, and Y Lin, and J Chen, and H Dai, and F Wang, and Y Xi, and H Thorlacius, and Z Qi
CD8+CD122+PD-1+ Tregs Synergize With Costimulatory Blockade of CD40/CD154, but Not B7/CD28, to Prolong Murine Allograft Survival.
January 2019, Frontiers in immunology,
Copied contents to your clipboard!